This will be a randomized, single-dose, open-label, two-period crossover study in 16 healthy
subjects. The study will consist of two phases: Pre-randomization and Randomization. The
Pre-randomization phase will have two periods: Screening and Baseline. In the Randomization
Phase, subjects will be randomized to one of two possible treatment sequences (fed/fasted and
fasted/fed). In each period, subjects will receive a single capsule containing 10 mg
lenvatinib either with or without a standard breakfast. There will be a 2-week washout
between treatments.